Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 9, 2018 (9 years ago)

Tacrolimus USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Tacrolimus USP (Monohydrate) for prescription compounding, packaged in a) 1g (NDC 58597-8029-4); b) 5g (NDC 58597-8029-5), RX only, packed by American Pharmaceutical Ingredients, LLC 6650 Highland Road, Waterford, MI 48327

Affected NDCs 58597-8029-04 58597-8029-05

Compare with the code on your package — it is the most precise check available.

Drug: Tacrolimus

Recalling firm
American Pharmaceutical Ingredients LLC
NDC code
58597-8029-4
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0523-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Tacrolimus recalls

See all
Class I · High risk

Prograf (tacrolimus)

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Ongoing Failed specification Astellas Pharma US Inc. NDC 0469-0607-73 D-0211-2025
Class I · High risk

Astagraf XL

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Ongoing Failed specification Astellas Pharma US Inc. NDC 0469-0647-73 D-0210-2025
Class II · Moderate risk

Tacrolimus Capsules

Presence of Foreign Tablets/Capsules: One 0.5 mg Tacrolimus capsule found in a bottle of 1 mg Tacrolimus capsules.

Terminated Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-526-01 D-0219-2024
Class II · Moderate risk

Tacrolimus Capsules

Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.

Ongoing Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-525-01 D-0330-2023

Other recalls by American Pharmaceutical Ingredients LLC

All 2018 recalls
Class II · Moderate risk

Sermorelin Acetate

Stability Data Does Not Support Expiry: Stability data from manufacturer does not support expiration dates listed.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-8092-1 D-0592-2018
Class II · Moderate risk

Oxytocin USP

Stability Data Does Not Support Expiry: Stability data from manufacturer does not support expiration dates listed.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-7042-3 D-0591-2018
Class II · Moderate risk

Fluticasone propionate USP

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-8276-3 D-0539-2018
Class II · Moderate risk

Cyanocobalamin USP

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-8044-1 D-0538-2018